SOURCE: Ablynx

October 20, 2008 12:01 ET


GHENT, BELGIUM--(Marketwire - October 20, 2008) - GHENT, Belgium, 20 October, 2008 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today that a consortium, comprising DG Infra+, B.S.I. and Foremost Immo, has committed to invest in the development of a 10,000 m2 cutting-edge laboratory facility (the Bio-Accelerator) on the Technologiepark in Zwijnaarde, Ghent. This facility will be close to Ablynx's existing facilities and the company has secured the right to use 70% of the capacity of the Bio-Accelerator, which is expected to be completed by mid-2010.

"We are very pleased to have secured this agreement with the consortium. This allows us to further establish a centre of excellence for Nanobody® technology in Ghent and consolidate our Belgian operations in the state-of-the-art Bio-Accelerator," said Dr Edwin Moses, Chief Executive Officer and Chairman of Ablynx. "Ablynx will have approximately two hundred staff by the end of 2008 and remains on track to become one of Europe's leading biotechnology companies, with the goal of filing five IND equivalents for our wholly-owned products by 2012."

For more information, please contact:

College Hill Life Sciences - for UK/International media enquiries:
Sue Charles, Justine Lamond, John McIntyre
t:   +44 (0)20 7866 7857
f:   +44 (0)20 7866 7900

Dr Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68

Eva-Lotta Allan
Chief Business Officer
t:   +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 / +44 (0)7990 570 900

Wim Ottevaere
Chief Financial Officer
t:   +32 (0)9 262 00 08

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Copyright © Hugin AS 2008. All rights reserved.

Contact Information